SRPK1 and breast carcinoma: In summary, our study has revealed that in at least some breast cancer cells, loss of Tip60-mediated SRPK1 acetylation may ultimately lead to anti-apoptotic AS events and predict poor outcome following cisplatin treatment (Supplementary Fig. 18).